Developing a biomarker for restless leg syndrome using genome wide DNA methylation data

Area of Science:

• Epigenetics
• Neuroscience
• Biomarker Discovery

Background:

• Restless Leg Syndrome (RLS) is a neurological disorder with complex etiology.
• Current diagnostic methods for RLS can be subjective and lack objective biomarkers.
• Epigenetic modifications, such as DNA methylation, are increasingly recognized as potential contributors to disease pathogenesis.

Purpose of the Study:

• To identify and validate an epigenetic biomarker for Restless Leg Syndrome (RLS) using whole genome DNA methylation data.
• To assess the predictive performance of the developed biomarker in independent peripheral blood and post-mortem neural tissue cohorts.
• To evaluate the biomarker's ability to predict iron deficiency anemia, a condition often associated with RLS.

Main Methods:

• Whole genome DNA methylation analysis was performed on lymphocyte samples from RLS patients and controls (discovery cohort).
• Statistical analyses including t-tests, linear regressions, and principal component analysis (PCA) were employed.
• The derived biomarker model was validated in peripheral blood and neural tissue replication cohorts, and in a dataset for iron deficiency anemia, using receiver-operating characteristic (ROC) analysis.

Main Results:

• An epigenetic biomarker model comprising 49 DNA methylation probes was identified.
• The model achieved an Area Under the Curve (AUC) of 87.5% for predicting RLS in the blood-based replication cohort.
• The biomarker demonstrated reasonable predictive performance in neural tissue (AUC 73.4%) and for iron deficiency anemia (AUC 83%).

Conclusions:

• A novel, blood-based epigenetic biomarker for RLS has been developed and validated.
• The biomarker shows promising replicability across different tissue types and in relation to iron deficiency anemia.
• Further research is warranted to elucidate underlying biological pathways and optimize the model for clinical application.